About

Sandeep Aggarwal is an Associate Professor of Clinical Medicine in the Department of Medicine at the Perelman School of Medicine, University of Pennsylvania. He specializes in renal-electrolyte and hypertension, with clinical expertise in glomerular diseases, diabetic kidney disease, complex hypertension, neuroendocrine hypertension, vascular medicine, nephrolithiasis, bone mineral disease, and point of care ultrasonography. Dr. Aggarwal is also the Director of Point of Care Ultrasonography at the Philadelphia VA Medical Center. He holds an MBBS degree from Pt Bhagwat Dayal Sharma Post-Grad Institute of Medical Sciences in Rohtak, India, obtained in 2003, and an MPA in Public Administration/Data Analytics from the University of Pennsylvania, expected in 2027. His research focuses on complex hypertension, diabetic kidney disease, cardiovascular risk, glomerular diseases, and data analytics involving large data modeling, machine learning, SQL, and GIS. Dr. Aggarwal has contributed to numerous publications in nephrology and hypertension, emphasizing translational research and clinical applications.

Research topics

• Internal medicine
• Medicine
• Surgery
• Intensive care medicine
• Remote sensing
• Radiology
• General surgery

Selected publications

• Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials

  JAMA Cardiology · 2023 · 82 citations

  • Medicine
  • Internal medicine
  • Remote sensing

  Importance: Ultrasound renal denervation (uRDN) was shown to lower blood pressure (BP) in patients with uncontrolled hypertension (HTN). Establishing the magnitude and consistency of the uRDN effect across the HTN spectrum is clinically important. Objective: To characterize the effectiveness and safety of uRDN vs a sham procedure from individual patient-level pooled data across uRDN trials including either patients with mild to moderate HTN on a background of no medications or with HTN resistant to standardized triple-combination therapy. Data Sources: A Study of the ReCor Medical Paradise System in Clinical Hypertension (RADIANCE-HTN SOLO and TRIO) and A Study of the ReCor Medical Paradise System in Stage II Hypertension (RADIANCE II) trials. Study Selection: Trials with similar designs, standardized operational implementation (medication standardization and blinding of both patients and physicians to treatment assignment), and follow-up. Data Extraction and Synthesis: Pooled analysis using individual patient-level data using linear regression models to compare uRDN with sham across the trials. Main Outcomes and Measures: The primary outcome was baseline-adjusted change in 2-month daytime ambulatory systolic BP (dASBP) between groups. Results: A total of 506 patients were randomized in the 3 studies (uRDN, 293; sham, 213; mean [SD] age, 54.1 [9.3]; 354 male [70.0%]). After a 1-month medication stabilization period, dASBP was similar between the groups (mean [SD], uRDN, 150.3 [9.2] mm Hg; sham, 150.8 [10.5] mm Hg). At 2 months, dASBP decreased by 8.5 mm Hg to mean (SD) 141.8 (13.8) mm Hg among patients treated with uRDN and by 2.9 mm Hg to 147.9 (14.6) mm Hg among patients treated with a sham procedure (mean difference, -5.9; 95% CI, -8.1 to -3.8 mm Hg; P < .001 in favor of uRDN). BP decreases from baseline with uRDN vs sham were consistent across trials and across BP parameters (office SBP: -10.4 mm Hg vs -3.4 mm Hg; mean difference, -6.4 mm Hg; 95% CI, -9.1 to -3.6 mm Hg; home SBP: -8.4 mm Hg vs -1.4 mm Hg; mean difference, -6.8 mm Hg; 95% CI, -8.7 to -4.9 mm Hg, respectively). The BP reductions with uRDN vs sham were consistent across prespecified subgroups. Independent predictors of a larger BP response to uRDN were higher baseline BP and heart rate and the presence of orthostatic hypertension. No differences in early safety end points were observed between groups. Conclusions and Relevance: Results of this patient-level pooled analysis suggest that BP reductions with uRDN were consistent across HTN severity in sham-controlled trials designed with a 2-month primary end point to standardize medications across randomized groups. Trial Registration: ClinicalTrials.gov Identifier: NCT02649426 and NCT03614260.

  PublisherOA PDFDOI

• Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program

  Circulation · 2023 · 35 citations

  • Medicine
  • Surgery
  • Internal medicine

  BACKGROUND: The randomized, sham-controlled RADIANCE-HTN (A Study of the Recor Medical Paradise System in Clinical Hypertension) SOLO, RADIANCE-HTN TRIO, and RADIANCE II (A Study of the Recor Medical Paradise System in Stage II Hypertension) trials independently met their primary end point of a greater reduction in daytime ambulatory systolic blood pressure (SBP) 2 months after ultrasound renal denervation (uRDN) in patients with hypertension. To characterize the longer-term effectiveness and safety of uRDN versus sham at 6 months, after the blinded addition of antihypertensive treatments (AHTs), we pooled individual patient data across these 3 similarly designed trials. METHODS: Patients with mild to moderate hypertension who were not on AHT or with hypertension resistant to a standardized combination triple AHT were randomized to uRDN (n=293) versus sham (n=213); they were to remain off of added AHT throughout 2 months of follow-up unless specified blood pressure (BP) criteria were exceeded. In each trial, if monthly home BP was ≥135/85 mm Hg from 2 to 5 months, standardized AHT was sequentially added to target home BP <135/85 mm Hg under blinding to initial treatment assignment. Six-month outcomes included baseline- and AHT-adjusted change in daytime ambulatory, home, and office SBP; change in AHT; and safety. Linear mixed regression models using all BP measurements and change in AHT from baseline through 6 months were used. RESULTS: <0.001), respectively. There was no heterogeneity between trials. Safety outcomes were few and did not differ between groups. CONCLUSIONS: This individual patient-data analysis of 506 patients included in the RADIANCE trials demonstrates the maintenance of BP-lowering efficacy of uRDN versus sham at 6 months, with fewer added AHTs. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT02649426 and NCT03614260.

  DOI

• Urinary Diversion: Core Curriculum 2021

  American Journal of Kidney Diseases · 2021 · 15 citations

  Senior authorCorresponding
  • Medicine
  • General surgery
  • Surgery
  DOI

Frequent coauthors

• Michel Azizi

  Hôpital Européen Georges-Pompidou

  33 shared

• Ajay J. Kirtane

  Cardiovascular Research Foundation

  32 shared

• Waqas Javed Siddiqui

  Indus Hospital

  22 shared

• Chikezie Alvarez

  Stanford Medicine

  18 shared

• Desmond Jay

  17 shared

• Ajay Jain

  St Bartholomew's Hospital

  17 shared

• Felix Mahfoud

  Universitätsklinikum des Saarlandes

  16 shared

• Howard J. Eisen

  Thomas Jefferson University Hospital

  15 shared

Labs

• Sandeep Aggarwal LabPI

Education

• Other, Medicine

  Pt Bhagwat Dayal Sharma Post-Grad Institute of Med. Sciences

  2003

• Other, Public Administration/Data Analytics

  University of Pennsylvania

  2027

Similar researchers at University of Pennsylvania

• John Q. Trojanowskih-296
• Craig B. Thompsonh-277
• Daniel J Raderh-236
• Carl H. Juneh-218
• M. Celeste Simonh-185